{
    "clinical_study": {
        "@rank": "72317", 
        "acronym": "OPTIMUS-A", 
        "arm_group": [
            {
                "arm_group_label": "tacrolimus", 
                "arm_group_type": "Active Comparator", 
                "description": "Control group: Tacrolimus + Corticosteroid (dual oral therapy)"
            }, 
            {
                "arm_group_label": "Mycophenolate Mofetil", 
                "arm_group_type": "Experimental", 
                "description": "Tacrolimus + Mycophenolate Mofetil+Corticosteroid (triple oral therapy)"
            }
        ], 
        "brief_summary": {
            "textblock": "Study to Compare the Safety and Efficacy of Tacrolimus and Steroids in Combination With\n      Mycophenolate Mofetil or Without Mycophenolate Mofetil in Liver Transplantation with\n      Hepatitis B Virus(HBsAg) Positive"
        }, 
        "brief_title": "TO Compare the Triple Drug Therapy and Dual Therapy .", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HEPATITIS", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women at the age of 20 to 65\n\n               -  Patients who will have primary Liver Transplantation becaused of Chronic\n                  Hepatitis B of HbsAg positive\n\n                    -  Having confirmed a result of HBsAg positive patients within 6 months prior\n                       to Screening point.\n\n                         -  Patients who will have Liver Transplantation from ABO-compatible or\n                            proper living donor \u2464 Patients who will receive investigational\n                            products for the entire period of clinical trial.\n\n                              -  Patients who have signed the informed consent after understanding\n                                 of clinical trial's purpose and risk.\n\n                                   -  For women of childbearing potential, pregnancy test negative\n                                      from urine or blood AND women who agree to contraception for\n                                      the entire period of clinical trial.\n\n        Exclusion Criteria:\n\n          -  Recipients who had Liver Transplantation OR who had or will have other organ\n             transplantation\n\n               -  Recipients who other organ transplantation in addition to liver at once.\n\n                    -  Recipients who will have Auxiliary Partial Orthotopic Liver\n                       Transplantation.\n\n                         -  Recipients who use a Bioartificial liver prior to Transplantation\n\n                              -  Cr > 2.0mg/dl at screening test\n\n                                   -  Patients who had malignant tumor within the past 5 years OR\n                                      have malignant tumor(except, successfully treated Skin's\n                                      non-metastatic basal cell carcinoma, squamous cell carcinoma\n                                      or primary hepatocellular carcinoma )\n\n                                        -  Recipients had hepatocellular carcinoma whick is out of\n                                           Milan criteria\n\n                                             -  WBC<1,500/mm3 or ANC<900/mm3 or PLT<30,000/mm3 at\n                                                Screening\n\n                                                  -  Investigator judge that a patient is not\n                                                     proper to enroll this study due to Severe\n                                                     digestive disorder at Screening\n\n                                                       -  Patients who have severe systemic\n                                                          infection (But the liver transplantation\n                                                          is excepted that performed after the\n                                                          infection is completely lost or\n                                                          well-controlled)\n\n                                                          \u246a Recipients who had Liver\n                                                          transplantation from HBsAg positive\n                                                          donor\n\n                                                          \u246b Recipients or Donors are HIV, HCV\n                                                          Positive\n\n                                                          \u246c Patients who need to systemc\n                                                          chemotherapy or immunosuppressive\n                                                          therapy prior to transplantation or took\n                                                          immunosuppressants within 30 days prior\n                                                          to liver transplantation(except,\n                                                          investigational products per protocol\n                                                          and corticosteroid)\n\n                                                          \u246d Patients who have hypersensitivity to\n                                                          mycophenolate, mycophenolate acid,\n                                                          ingredient of investigational products,\n                                                          tacrolimus , Macrolide antibiotic and\n                                                          Steroids\n\n                                                          \u246e Patients who had been received or have\n                                                          been received other investigational\n                                                          products within 28 days prior to\n                                                          screening 16 Pregnant women and\n                                                          lactating women 17 Substance abuse\n                                                          patient, mentally defective person or\n                                                          patients who is not possible to\n                                                          participate in clinical trial by law 18\n                                                          Investigator judge that a patient have\n                                                          communication disorder 19 Patients are\n                                                          not capable of visiting accor.ding to\n                                                          study visit schedule 20 Investigator\n                                                          judge that a patient is not proper to\n                                                          enroll this study, et cetera"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075242", 
            "org_study_id": "2011-0900", 
            "secondary_id": "2011-0900"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mycophenolate Mofetil", 
                "description": "experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule\u00ae(Mycophenolate Mofetil),", 
                "intervention_name": "Mycophenolate Mofetil", 
                "intervention_type": "Drug", 
                "other_name": "Tacrolimus + Mycophenolate Mofetil+Corticosteroid"
            }, 
            {
                "arm_group_label": [
                    "tacrolimus", 
                    "Mycophenolate Mofetil"
                ], 
                "description": "control group receive same immunosuppressants except for My-rept capsule\u00ae(Mycophenolate Mofetil- investigational product", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": "Tacrolimus + Corticosteroid"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mycophenolate mofetil", 
                "Tacrolimus", 
                "Mycophenolic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "HBV", 
        "lastchanged_date": "February 28, 2014", 
        "location": {
            "contact": {
                "email": "sglee2@amc.seoul.kr", 
                "last_name": "Sung-Gyu Lee"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Korea"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Sung-Gyu Lee", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open Label, Multi-center, Randomized Study to Compare of Tacrolimus and Steroids in Combination With Mycophenolate Mofetil or Without Mycophenolate Mofetil in Liver Transplantation With Hepatitis B Virus(HBsAg) Positive", 
        "overall_contact": {
            "last_name": "yun-kyoung kim", 
            "phone": "82-31-219-4467"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Sung-Gyu Lee", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\u2022\tIncidence rate has been confirmed acute cellular rejection(RAI 4 and over) from liver biopsy", 
            "measure": "rejection", 
            "safety_issue": "No", 
            "time_frame": "within 6months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075242"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Sung-Gyu Lee", 
            "investigator_title": "Professor, Department of surgery, Asan medical center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tRecurrence rate of HBV after liver transplantation for 24 weeks (HBsAg Positve)", 
                "measure": "rate of HBV", 
                "safety_issue": "No", 
                "time_frame": "within 6 months"
            }, 
            {
                "description": "\u2022\tPatients survival rate after liver transplantation for 24 weeks / Graft survival rate", 
                "measure": "Graft survival rate", 
                "safety_issue": "No", 
                "time_frame": "within 6 months"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}